About HATIP

A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.

Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.

Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.

latest aidsmap news

• Brazil rejects tenofovir patent
• Fibrosis linked to rapid loss of gut CD4 cells after HIV infection
• Poor results using non-medical HIV counsellors to screen for treatment eligibility in Malawi
• Raltegravir may cause temporary worsening of pre-existing depression
• Etravirine (<i>Intelence</i>) approved in Europe for treatment-experienced patients
• Belief in conspiracy theories means less HIV testing in South Africa
• Case report - viral load undetectable in blood, but detectable in semen
• 'Hidden epidemic' of HIV amongst African migrants in the United States
• Blood viral load predicts HIV transmission better than semen viral load in small study among MSM
• Infectiousness and antiretroviral therapy: reports look set to further fuel the debate